Upper GI 2016

PRE-OPERATIVE treatments improve OS

N population

Type

mOS (months)

3-year Survival (%)

Kelsen, 1998

440 46% SCC 54% ADC 802 31% SCC 69% adc

Surg +/- CT

14.9 vs 16.1

26 vs 23

MRC, 2002 Allumet, 2009

Surg +/- CT

13.3 vs 16.8

17 vs 23 (5 yrs)

✔

Cunningham,

503 74%adc gastr

Surg +/-

NR

23 vs 36

✔

Chimiothérapie Préopératoire

2006

26%adc oeso CT p rio ératoire

(5 yrs)

Le Prise, 1994

86 100% SCC

Surg +/- RTCT

10.0 vs 10.0

47 vs 47 (1 yr)

Walsh, 1996

103 100% ADC

Surg +/- RTCT

11.0 vs 16.0

6 vs 32

✔

Bosset, 1997

282 100% SCC

Surg +/- RTCT

18.6 vs 18.6

34 vs 36

Urba, 2001

100 25% SCC 75% ADC

Surg +/- RTCT

17.6 vs 16.9

16 vs 30

Burmeister, 2005 256 37% SCC 63% ADC

Surg +/- RTCT

22.2 vs 19.3

NR

Tepper, 2008

56

25% SCC 75% ADC

Surg +/- RTCT

21.5 vs 53.8

16 vs 39 (5 yrs)

✔